ストックスクリーナーアプリを入手
7.16
2.05%
-0.15
アフターアワーズ：
7.06
-0.10
-1.40%
前日終値:
$7.31
開ける：
$7.15
24時間の取引高:
93,882
Relative Volume:
0.94
時価総額：
$214.29M
収益：
$31.37M
当期純損益:
$-53.77M
株価収益率:
-4.9254
EPS:
-1.4537
ネットキャッシュフロー:
$-49.02M
1週間 パフォーマンス:
-1.92%
1か月 パフォーマンス:
+37.96%
6か月 パフォーマンス:
+93.51%
1年 パフォーマンス:
-58.61%
1日の値動き範囲:
$7.02
$7.39
1週間の範囲:
$6.92
$7.75
52週間の値動き範囲:
$1.97
$18.29
Silence Therapeutics Plc Adr Stock (SLN) Company Profile
名前
Silence Therapeutics Plc Adr
セクター
電話
44-0-20-3457 6900
住所
72 HAMMERSMITH ROAD, LONDON
SLN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SLN
Silence Therapeutics Plc Adr
|
7.16 | 345.28M | 31.37M | -53.77M | -49.02M | -1.4537 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 398.11M | -1.03B | -868.57M | -5.7032 |
Silence Therapeutics Plc Adr Stock (SLN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-11 | 開始されました | Goldman | Sell |
| 2024-12-02 | 繰り返されました | BMO Capital Markets | Outperform |
| 2024-09-03 | 開始されました | Jefferies | Buy |
| 2024-01-31 | 開始されました | BMO Capital Markets | Outperform |
Silence Therapeutics Plc Adr (SLN) 最新ニュース
5 Under-the-Radar Biotech Stocks That Could Soar in 2026 - Barchart.com
Silence Therapeutics completes enrollment in PV treatment study - Investing.com
Check Out Insider Trades For Silence Therapeutics Plc ADR (SLN) Stock - fostersleader.com
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives $32.60 Average Price Target from Analysts - Defense World
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
GAMMA Investing LLC Buys 4,773 Shares of Silence Therapeutics PLC Sponsored ADR $SLN - Defense World
Goldman Sachs Group Inc. Sells 12,510 Shares of Silence Therapeutics PLC Sponsored ADR $SLN - Defense World
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives $32.60 Consensus Target Price from Analysts - Defense World
Australia Acute Respiratory Distress Syndrome Market Growth and Company Report 2025-2033 Featuring Silence Therapeutics, Gilead Sciences, Terumo, Getinge, Livanova, Medtronic, Fresenius, Nipro, Pfizer - GlobeNewswire Inc.
Silence Therapeutics (OTCMKTS:SLNCF) Shares Down 5% – Here’s What Happened - Defense World
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Silence Therapeutics (SLN) Stock Price, News & Analysis - MarketBeat
Silence Therapeutics director Michael Davidson resigns from board - Investing.com
Silence Therapeutics director Michael Davidson resigns from board By Investing.com - Investing.com India
William Blair Issues Pessimistic Forecast for SLN Earnings - Defense World
Silence Therapeutics earnings missed by $0.06, revenue fell short of estimates - Investing.com South Africa
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives $33.83 Average PT from Analysts - Defense World
Wall Street Analysts Believe GH Research (GHRS) Could Rally 107.25%: Here's is How to Trade - Yahoo.co
Stephens Inc. AR Invests $260,000 in Evergy Inc. (NASDAQ:EVRG) - Defense World
Sonnet BioTherapeutics (NASDAQ:SONN) Stock Price Up 20.7% – Still a Buy? - Defense World
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Beat the Market the Zacks Way: Credo, Palantir, Oracle in Focus - Nasdaq
Silence Therapeutics soars 67% following InvestingPro’s Fair Value signal By Investing.com - Investing.com
H.C. Wainwright reiterates buy rating on Silence Therapeutics stock By Investing.com - Investing.com South Africa
Wall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a Bet - MSN
Silence Therapeutics’s SWOT analysis: gene therapy stock faces pivotal year By Investing.com - Investing.com India
Silence Therapeutics’s SWOT analysis: gene therapy stock faces pivotal year - Investing.com
Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to Trade - MSN
Silence Therapeutics stock hits 52-week low at $3.19 - Investing.com
Silence Therapeutics (SLN) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Earnings call transcript: Silence Therapeutics sees stock rise post-earnings - Investing.com
Silence Therapeutics's SWOT analysis: stock poised for growth amid challenges - Investing.com
Top 3 Health Care Stocks That May Explode In Q4 - Benzinga
SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels - Zacks Investment Research
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.28% - Investing.com
Silence Therapeutics stock holds Buy rating on positive trial results By Investing.com - Investing.com UK
Silence Therapeutics director Alistair Gray retires - Investing.com
Zerlasiran shows promise in lowering cardiovascular risk - Investing.com
Silence Therapeutics PLC Sponsored ADR (SLN) Soars 6.4%: Is Further Upside Left in the Stock? - Yahoo Finance
Silence Therapeutics: Multiple 2024 Catalysts Make This mRNA Biotech Worth A Look - Seeking Alpha
Recursion Pharmaceuticals (RXRX) Surges 13.8%: Is This an Indication of Further Gains? - Nasdaq
Silence Therapeutics to Join Guggenheim Biotech Conference By Investing.com - Investing.com South Africa
All You Need to Know About Silence Therapeutics PLC Sponsored ADR (SLN) Rating Upgrade to Strong Buy - Yahoo Finance
Here's Why Momentum in Silence Therapeutics PLC Sponsored ADR (SLN) Should Keep going - Nasdaq
Wall Street Analysts Predict a 361.54% Upside in Silence Therapeutics PLC Sponsored ADR (SLN): Here's What You Should Know - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
BioCryst (BCRX) Surges 9.9%: Is This an Indication of Further Gains? - Nasdaq
SLNCF Stock Price and Chart — OTC:SLNCF - TradingView
Claire Keast-Butler - Cooley
Our approach to nucleotide-based therapeutics - AstraZeneca
Silence Therapeutics Appoints J.P. Gabriel as Chief Technical Operations Officer - The Globe and Mail
Silence Therapeutics Plc Adr (SLN) 財務データ
収益
当期純利益
現金流量
EPS
1.62%
0.21%
大文字化:
|
ボリューム (24 時間):